Compact Point-of-Care Device for Self-Administered HIV Viral Load Tests from Whole Blood

Liu, Tianyi; Politza, Anthony J.; Kshirsagar, Aneesh; Zhu, Yusheng; Guan, Weihua

doi:10.1021/acssensors.3c01819

Cited by 5 publications

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, there is a focused endeavor to develop advanced devices capable of facilitating the loading of extraction and amplification reagents for the simultaneous, multiplexed detection of miRNA, aiming to simplify the detection process in POCT systems. Additionally, to enhance the longevity and transportability of reagents and chemicals (Liu et al, 2023; Noviana et al, 2021), the adoption of lyophilization technology is being explored. This approach would allow for extended storage and easier transportation of these materials, further improving the practicality and accessibility of miRNA detection technologies.…”

Section: Summary and Future Perspectivementioning

confidence: 99%

Sample‐to‐answer salivary miRNA testing: New frontiers in point‐of‐care diagnostic technologies

Zhang,

Liu,

Dong

et al. 2024

WIREs Nanomed Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

MicroRNA (miRNA), crucial non‐coding RNAs, have emerged as key biomarkers in molecular diagnostics, prognosis, and personalized medicine due to their significant role in gene expression regulation. Salivary miRNA, in particular, stands out for its non‐invasive collection method and ease of accessibility, offering promising avenues for the development of point‐of‐care diagnostics for a spectrum of diseases, including cancer, neurodegenerative disorders, and infectious diseases. Such development promises rapid and precise diagnosis, enabling timely treatment. Despite significant advancements in salivary miRNA‐based testing, challenges persist in the quantification, multiplexing, sensitivity, and specificity, particularly for miRNA at low concentrations in complex biological mixtures. This work delves into these challenges, focusing on the development and application of salivary miRNA tests for point‐of‐care use. We explore the biogenesis of salivary miRNA and analyze their quantitative expression and their disease relevance in cancer, infection, and neurodegenerative disorders. We also examined recent progress in miRNA extraction, amplification, and multiplexed detection methods. This study offers a comprehensive view of the development of salivary miRNA‐based point‐of‐care testing (POCT). Its successful advancement could revolutionize the early detection, monitoring, and management of various conditions, enhancing healthcare outcomes.This article is categorized under: Diagnostic Tools > Biosensing Diagnostic Tools > Diagnostic Nanodevices

show abstract

Section: Summary and Future Perspectivementioning

confidence: 99%

Sample‐to‐answer salivary miRNA testing: New frontiers in point‐of‐care diagnostic technologies

Zhang,

Liu,

Dong

et al. 2024

WIREs Nanomed Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

show abstract

Two‐Stage Mixed‐Dye‐Based Isothermal Amplification with Ribonuclease‐Cleavable Enhanced Probes for Dual‐Visualization Detection of SARS‐CoV‐2 Variants of Interest

Ding,

Wang,

Gui

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Rapid and visual detection of SARS‐CoV‐2 variants is vital for timely assessment of variant transmission in resource‐limited settings. Here, a closed‐tube, two‐stage, mixed‐dye‐based isothermal amplification method with ribonuclease‐cleavable enhanced probes (REP), termed REP‐TMAP, for dual‐visualization detection of SARS‐CoV‐2 variants including JN.1, BA.2, BA.4/5, and Delta is introduced. The first stage of REP‐TMAP is reverse transcription recombinase polymerase amplification and the second stage is dual‐visualization detection synergistically mediated by the REP and the mixed dyes of cresol red and hydroxy naphthol blue. In REP‐TMAP reaction, the color change under ambient light indicates SARS‐CoV‐2 infection, while the fluorescence change under blue light excitation specifies variant type. On detecting transcribed RNA of SARS‐CoV‐2 spike gene, this assay is rapid (within 40 min), highly sensitive (10–200 copies per reaction), and highly specific (identification of single‐base mutations). Furthermore, the assay has been clinically validated to accurately detect JN.1, BA.2, and BA.4/5 variants from 102 human oropharyngeal swabs. The proposed assay therefore holds great potentials to provide a rapid, dual‐visualization, sensitive, specific, point‐of‐care detection of SARS‐CoV‐2 variants and beyond.

show abstract

Diffusion-driven height readout analytical device based on gold nanobipyramid-doped supramolecular hydrogel for point-of-care bioanalysis

Gong,

Li,

She

et al. 2024

Sensors and Actuators B: Chemical

View full text Add to dashboard Cite

Compact Point-of-Care Device for Self-Administered HIV Viral Load Tests from Whole Blood

Cited by 5 publications

References 55 publications

Sample‐to‐answer salivary miRNA testing: New frontiers in point‐of‐care diagnostic technologies

Sample‐to‐answer salivary miRNA testing: New frontiers in point‐of‐care diagnostic technologies

Two‐Stage Mixed‐Dye‐Based Isothermal Amplification with Ribonuclease‐Cleavable Enhanced Probes for Dual‐Visualization Detection of SARS‐CoV‐2 Variants of Interest

Diffusion-driven height readout analytical device based on gold nanobipyramid-doped supramolecular hydrogel for point-of-care bioanalysis

Contact Info

Product

Resources

About